Invivyd, Inc. (IVVD) Stock Price & Analysis
Invivyd, Inc. (IVVD) fell 2.94% to USD 0.99 as of June 10, 2026 at 01:55 UTC, according to Nexqual real-time market data.
IVVD last closed at USD 1.02; the session ranged USD 0.97–1.05 on volume of 5,388,505 shares. Market capitalization is $291.66M, with a 52-week range of USD 0.48–3.07 (NGM). Source: Nexqual, June 10, 2026 at 01:55 UTC.
Key Statistics (as of June 10, 2026 at 01:55 UTC)
| Price | USD 0.99 |
|---|---|
| Change | ▼ 2.94% (down) |
| Previous Close | USD 1.02 |
| Open | USD 1.03 |
| Day Range | USD 0.97 – 1.05 |
| 52-Week Range | USD 0.48 – 3.07 |
| Volume | 5,388,505 shares |
| Market Cap | $291.66M |
| Exchange | NGM |
Technical Analysis (IVVD)
Nexqual's technical model rates IVVD "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.58 (neutral) |
| vs SMA50 | Below (USD 1.35) |
| MACD | -0.1 (negative) |
Analyst Ratings (IVVD)
Wall Street analysts rate IVVD "Strong Buy" based on 3 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of June 10, 2026 at 01:55 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (IVVD)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $14.40M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.08 ▼ miss |
| 2025-09-30 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-06-30 | USD -0.12 vs est 0.01 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Financials & Fundamentals (IVVD)
| Total Revenue | $55.87M |
|---|---|
| Revenue Growth (YoY) | +21.60% |
| Gross Margin | +92.94% |
| Operating Margin | -313.85% |
| Profit Margin | -138.90% |
| ROE | -60.34% |
| Debt / Equity | 4.25 |
| Current Ratio | 6.47 |
| Total Cash | $184.15M |
| Total Debt | $8.63M |
| Free Cash Flow | $-50.10M |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Financial Health Score (IVVD)
Nexqual rates Invivyd, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:55 UTC.
| Growth | Strong — Revenue +110% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $184M cash vs $9M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$50M, burning cash |
| Efficiency | Critical — ROE -60%, ROA -29.6% |
Ownership (IVVD)
| Insider Ownership | +7.07% |
|---|---|
| Institutional Ownership | +83.87% |
| Shares Outstanding | 294.61M |
| Float | 214.30M |
| Short % of Float | +11.60% |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Leadership (IVVD)
Invivyd, Inc. is led by William E. Duke Jr. (age 53), CFO, Principal Accounting Officer & Principal Executive Officer, per Nexqual as of June 10, 2026 at 01:55 UTC.
| CFO, Principal Accounting Officer & Principal Executive Officer | William E. Duke Jr. (age 53) |
|---|---|
| Chief Scientific Officer | Robert D. Allen (age 55) |
| Senior Vice President of Regulatory Affairs | Rachael Gerlach |
| Senior Vice President of Finance | Katie Falzone |
Major Backers & Investors (IVVD)
Notable institutional backers of Invivyd, Inc. include Janus Henderson Group PLC, Perceptive Advisors Llc, BVF Inc., according to Nexqual as of June 10, 2026 at 01:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 11.23% |
| Perceptive Advisors Llc | 7.08% |
| BVF Inc. | 6.63% |
| Maverick Capital Ltd. | 6.44% |
| Saturn V Capital Management LP | 3.72% |
| M28 Capital Management LP | 3.14% |
| Eventide Asset Management LLC | 3.08% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 3.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.73% |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
From Invivyd, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Under the Adimab Platform Transfer Agreement, we were granted the right 14   under certain intellectual property of Adimab to practice certain elements of Adimab's platform technology, including B-cell cloning using Adimab's proprietary yeast cell lines and other antibody optimization libraries, trade secrets, protocols and software of Adimab, to discover, engineer and optimize antibodies.
- In August 2025, we announced alignment with advice from the FDA on a compact and, therefore, rapid pathway to potential Biologics License Application ("BLA") approval for VYD2311 for the prevention of COVID-19.
- Through our proprietary technology platform, we continue to investigate additional mAbs for protection and treatment of other important infectious diseases, such as measles.
- We have exclusive access to Adimab's industry-leading B-cell mining, protein and antibody engineering capabilities for coronavirus antibody discovery.
Partnerships
- Population Health Partners In November 2022 (the "PHP Effective Date"), we entered into a Master Services Agreement with Population Health Partners, L.P. ("PHP"), pursuant to which PHP agreed to provide services and create deliverables for us as agreed between us and PHP and set forth in one or more work orders under such agreement (the "PHP MSA").
- In 2022, we secured dedicated laboratory space and expanded our research team in order to enable internal discovery and development of our mAb candidates, while continuing to leverage our existing partnership with Adimab, LLC ("Adimab"), including Adimab's platform technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.94 | ▼ 1.02% |
| XLO | Xilio Therapeutics, Inc. | USD 7.9 | ▲ 2.6% |
| ACON | Aclarion, Inc. | USD 3.26 | ▼ 8.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:55 UTC. This page is informational and not investment advice.